ClinicalTrials.gg
CompletedNCT06221969Updated Oct 19, 2026

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

A Phase 3 interventional study of Cagrilintide and Semaglutide in Type 2 Diabetes, sponsored by Novo Nordisk A/S. Completed at 197 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,024
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing cagrilintide in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, 4 of them phase 3. cagrilintide · Diabetes Mellitus, Type 2.

Enrollment
4th of 15
1,024 · median 274
Started
2024
with 5 others
Phase 3
10 of 15
3 open now
Registered
5th of 15
by date
Lead sponsor
15 of 15
Novo Nordisk A/S

Among the 15 studies testing cagrilintide in Diabetes Mellitus, Type 2, this one is the 4th largest by enrollment, is one of 6 that started in 2024, is one of 10 in phase 3, and was the 5th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 15 studies testing cagrilintide in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About cagrilintide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing cagrilintide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This study will look at how well CagriSema helps people with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema. CagriSema will be compared to a medicine called tirzepatide that doctors may prescribe in some countries. Participants will get either CagriSema or tirzepatide. Which treatment participant get is decided by chance like flipping a coin. Participant will have an equal chance of receiving either drug. For each participant, the study will last for up to one and a half years.

03

Conditions studied

  • Type 2 Diabetes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female (sex at birth).
  • Age 18 years or above at the time of signing the .
  • Diagnosed with type 2 diabetes ≥ 180 days before screening.
  • Stable daily dose(s) ≥ 90 days before screening of any of the following antidiabetic drug(s) or combination regimen(s) at effective or maximum tolerated dose as judged by the investigator: metformin with or without an sodium-glucose co-transporter-2 (SGLT2) inhibitor.
  • 7.0-10.5% (53-91 mmol/mol) (both inclusive) as determined by central laboratory at screening.
  • (BMI) of ≥ 30.0 kilogram per square meter (kg/m\^2) at screening. BMI will be calculated in the electronic case report form (eCRF) based on height and body weight at screening.

Exclusion criteria

Exclusion Criteria:

  • Female who is pregnant, breast-feeding or intends to become pregnant or is of and not using a highly effective method.
  • Renal impairment with estimated \< 30 milliliter per minute per 1.73 square meter (mL/min/1.73 m\^2) as determined by central laboratory at screening.
  • Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed.
  • Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by an eye examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,024 participants (actual)

Study arms

  • Experimental
    CagriSema

    Participants will receive cagrilintide dose 1 and semaglutide dose 2 subcutaneously once-weekly (dose escalation period of 16 weeks) for up to 68 weeks.

    Drug: Cagrilintide · Drug: Semaglutide

  • Active comparator
    Tirzepatide

    Participants will receive tirzepatide dose 1 subcutaneously once-weekly (dose escalation period of 20 weeks) for up to 68 weeks.

    Drug: Tirzepatide

Interventions

  • Cagrilintide will be administered subcutaneously.

  • Semaglutide will be administered subcutaneously.

  • Tirzepatide will be administered subcutaneously.

06

What researchers measure

Primary outcomes

  1. Change in glycated haemoglobin (HbA1c)

    Measured in percentage (%)-points.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  2. Relative change in body weight

    Measured in percentage (%).

    Time frame: From baseline (week 0) to end of treatment (week 68)

Secondary outcomes

  1. Change in HbA1c

    Measured in %-points.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  2. Change in fasting plasma glucose (FPG)

    Measured in millimoles per liter (mmol/L).

    Time frame: From baseline (week 0) to end of treatment (week 68)

  3. Achievement of HbA1c target values of less than (<) 7.0% (<53 millimole per mole [mmol/mol])

    Count of participant

    Time frame: At end of treatment (week 68)

  4. Achievement of HbA1c target values of less than or equal to (≤) 6.5% (≤ 48 mmol/mol)

    Count of participant

    Time frame: From baseline (week 0) to end of treatment (week 68)

  5. Achievement of greater than or equal to (≥) 5% weight reduction

    Count of participant

    Time frame: From baseline (week 0) to end of treatment (week 68)

  6. Achievement of ≥ 10% weight reduction

    Count of participant

    Time frame: From baseline (week 0) to end of treatment (week 68)

  7. Achievement of ≥ 15 % weight reduction

    Count of participant

    Time frame: From baseline (week 0) to end of treatment (week 68)

  8. Achievement of ≥ 20 % weight reduction

    Count of participant

    Time frame: From baseline (week 0) to end of treatment (week 68)

  9. Change in systolic blood pressure

    Measured in millimeters of mercury(mmHg).

    Time frame: From baseline (week 0) to end of treatment (week 68)

  10. Change in diastolic blood pressure

    Measured in mmHg.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  11. Change in waist circumference

    Measured in centimeter (cm).

    Time frame: From baseline (week 0) to end of treatment (week 68)

  12. Ratio to baseline in lipids: Total cholesterol

    Measured in ratio.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  13. Ratio to baseline in lipids: High-density lipoprotein (HDL) cholesterol

    Measured in ratio.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  14. Ratio to baseline in lipids: Low-density lipoprotein (LDL) cholesterol

    Measured in ratio.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  15. Ratio to baseline in lipids: Very low-density lipoprotein (VLDL) cholesterol

    Measured in ratio.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  16. Ratio to baseline in lipids: Triglycerides

    Measured in ratio.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  17. Ratio to baseline in lipids: non-HDL cholesterol

    Measured in ratio.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  18. Change From Baseline in Short Form-36 Version 2 (SF-36v2) (Acute Version) Health Survey

    The SF-36 v2 will be used to measure differences in quality of life and mental wellbeing. The scores 0-100 (where higher scores indicated a better quality of life and mental wellbeing) from the SF-36 will be converted to a norm-based score using a T-score transformation in order to obtain a direct interpretation in relation to the distribution of the scores in the 1998 United States general population. Measured as score on a scale.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  19. Change in Impact of Weight on Quality of Life-Lite Clinical Trials (IWQOL-Lite-CT) version 3

    IWQOL-Lite-CT measures weight-related physical and psychosocial functioning. The measure consists of 20 items yielding 3 composite scores, and 1 total score. Higher scores indicate better levels of functioning. Composite scores (score range): Physical composite (0-100), Psychosocial composite (0-100), Physical Function composite (0-100). Total score (0-100). Higher scores indicate better level of functioning.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  20. Number of Treatment-emergent Adverse Events (TEAEs)

    Count of events

    Time frame: From baseline (week 0) to end of study (week 74)

  21. Number of clinically significant hypoglycaemic episodes (level 2) (<3.0 mmol/L (<54 milligram per deciliter [mg/dL]), confirmed by blood glucose meter)

    Count of episodes

    Time frame: From baseline (week 0) to end of study (week 74)

  22. Number of severe hypoglycaemic episodes (level 3): hypoglycaemia associated with severe cognitive impairment requiring external assistance for recovery, with no specific glucose threshold

    Count of episodes

    Time frame: From baseline (week 0) to end of study (week 74)

07

Study locations

197 sites
  • Synexus Clin Res-Birmingham
    Birmingham, Alabama 35211, United States
  • Univ of Alabama_Birmingham
    Birmingham, Alabama 35233, United States
  • Prime Medical Group, LLC
    Gilbert, Arizona 85296, United States
  • Velocity Clinical Research-Phoenix
    Phoenix, Arizona 85006, United States
  • Synexus Rsch /Cnt Phnx Med C
    Phoenix, Arizona 85020, United States
  • Arkansas Clinical Research
    Little Rock, Arkansas 72205, United States
  • Unity Health-Searcy Medical Center
    Searcy, Arkansas 72143, United States
  • Velocity Clin Res-Chula Vista
    Chula Vista, California 91911, United States
  • Headlands Research California, LLC
    Escondido, California 92025, United States
  • Neighborhood Healthcare
    Escondido, California 92025, United States
  • St. Jude Heritage Yorba Linda - Pediatric Ste D
    Fullerton, California 92835, United States
  • Diabetes & Endocrine Specialists - La Mesa
    La Mesa, California 91942, United States
  • Diabetes and Endocrine Specialists - La Mesa
    La Mesa, California 91942, United States
  • Velocity Clin Res San Diego
    La Mesa, California 91942, United States
  • Headlands Research CTR Lincoln
    Lincoln, California 95648, United States
  • Loma Linda Univ Hlth Cr Endo
    Loma Linda, California 92354, United States
  • Valley Clinical Trials, Inc.
    Northridge, California 91325, United States
  • Desert Oasis Healthcare
    Palm Springs, California 92262, United States
  • Velocity Clin Res - Panorama
    Panorama City, California 91402, United States
  • Western University of Health Sciences
    Pomona, California 91766, United States
  • Endocrinology Josel Cabaccan
    San Jose, California 95148, United States
  • Mills-Peninsula Medical Center
    San Mateo, California 94401, United States
  • NorCal Endocrinology and Internal Medicine
    San Ramon, California 94583, United States
  • Premier Medical Center, Inc.
    Toluca Lake, California 91602, United States
  • Velocity Clin Res - Panorama
    Van Nuys, California 91405, United States
  • Diablo Clinical Research, Inc.
    Walnut Creek, California 94598, United States
  • University of Colorado Hospital
    Aurora, Colorado 80045, United States
  • Optumcare Clinical Trials,LLC-Golden
    Colorado Springs, Colorado 80906, United States
  • Northeast Res Inst. Inc.
    Jacksonville, Florida 32204, United States
  • Bioclinical Research Alliance
    Miami, Florida 33155, United States
  • New Horizon Research Center
    Miami, Florida 33165, United States
  • South Broward Research LLC
    Miramar, Florida 33027, United States
  • West Orange Endocrinology
    Ocoee, Florida 34761, United States
  • Optimal Research Sites
    Orange City, Florida 32763, United States
  • Trans Res Inst for Met & Diab
    Orlando, Florida 32804, United States
  • Oviedo Medical Research, LLC
    Oviedo, Florida 32765, United States
  • Center for Diab,Obes & Metab
    Pembroke Pines, Florida 33024, United States
  • Hope Clin Res & Wellness
    Conyers, Georgia 30094, United States
  • Center for Adv Res & Education
    Gainesville, Georgia 30501, United States
  • Urban Family Practice Assoc
    Marietta, Georgia 30067, United States
  • Endocrine Research Solutions
    Roswell, Georgia 30076, United States
  • Pacific Diabetes & Endo Ctr
    Honolulu, Hawaii 96813, United States
  • St. Luke's Health System
    Boise, Idaho 83702, United States
  • Solaris Clinical Research
    Meridian, Idaho 83646, United States
  • Cedar-Crosse Research Center
    Chicago, Illinois 60607, United States
  • Clinical Invest Special_Gurnee
    Gurnee, Illinois 60031, United States
  • Endeavor Health
    Skokie, Illinois 60077, United States
  • Evanston Premier Hlthcr Res
    Skokie, Illinois 60077, United States
  • American Health Network of Indiana, LLC_Greenfield
    Greenfield, Indiana 46140, United States
  • Iowa Diabetes & Endo Res Ctr
    West Des Moines, Iowa 50266, United States
  • Cotton-O'Neil Diab & Endo Ctr
    Topeka, Kansas 66606, United States
  • Velocity Clin Res Lafayette
    Lafayette, Louisiana 70508, United States
  • MedStar Hlth Res Institute
    Hyattsville, Maryland 20782, United States
  • Joslin Diabetes Center
    Boston, Massachusetts 02215, United States
  • International Diabetes Center
    Minneapolis, Minnesota 55416, United States
  • Belzoni Clinical Research
    Belzoni, Mississippi 39038, United States
  • Velocity Clin Res Gulfport
    Gulfport, Mississippi 39503, United States
  • Diabetes & Endo Specialists Inc
    Chesterfield, Missouri 63017, United States
  • StudyMetrix Research LLC
    City of Saint Peters, Missouri 63303, United States
  • Amicis Centers of Clinical Research
    St Louis, Missouri 63128, United States
  • Velocity Clin Res Albuquerque
    Albuquerque, New Mexico 87107, United States
  • AMC Community Endocrinology
    Albany, New York 12203, United States
  • Velocity Clin Res Syracuse
    East Syracuse, New York 13057, United States
  • Southgate Medical Group, LLP
    West Seneca, New York 14224, United States
  • UNC Eastowne Clinical Research Unit
    Chapel Hill, North Carolina 27514, United States
  • PharmQuest Life Sciences LLC
    Greensboro, North Carolina 27408, United States
  • Carteret Medical Group
    Morehead City, North Carolina 28557, United States
  • Centricity Rsrch MHCity Multi
    Morehead City, North Carolina 28557, United States
  • Piedmont Healthcare/Research
    Statesville, North Carolina 28625, United States
  • Accellacare
    Wilmington, North Carolina 28401, United States
  • Plains Clinical Research Center, LLC
    Fargo, North Dakota 58104, United States
  • Remington Davis Inc
    Columbus, Ohio 43215, United States
  • Advanced Medical Research
    Maumee, Ohio 43537, United States
  • New Venture Medical Research
    Wadsworth, Ohio 44281-9236, United States
  • Lynn Institute of Norman
    Norman, Oklahoma 73072, United States
  • CCT Research
    Horsham, Pennsylvania 19044, United States
  • Thomas Jefferson University_Philadelphia
    Philadelphia, Pennsylvania 19114, United States
  • Clinical Res Collaborative
    Cumberland, Rhode Island 02864, United States
  • Velocity Clin Res Providence
    East Greenwich, Rhode Island 02818, United States
  • Velocity Clinical Res-Anderson
    Anderson, South Carolina 29621, United States
  • Trial Management Associates
    Myrtle Beach, South Carolina 29572, United States
  • Hillcrest Clinical Research
    Simpsonville, South Carolina 29681-1538, United States
  • Spartanburg Medical Research
    Spartanburg, South Carolina 29303, United States
  • AM Diabetes And Endocrinology Center
    Bartlett, Tennessee 38133, United States
  • Holston Medical Group Pc
    Bristol, Tennessee 37620, United States
  • Univ Diab & Endo Consultants
    Chattanooga, Tennessee 37411, United States
  • Jackson Clinic
    Jackson, Tennessee 38305, United States
  • Holston Medical Group
    Kingsport, Tennessee 37660, United States
  • Clinical Neuroscience Solutions
    Memphis, Tennessee 38119, United States
  • HealthStar Physicians PC
    Morristown, Tennessee 37813, United States
  • Clinical Research Associates
    Nashville, Tennessee 37203, United States
  • Arlington Family Res. Ctr Inc
    Arlington, Texas 76012-4637, United States
  • Velocity Clin Res
    Austin, Texas 78759, United States
  • UT Health University of Texas
    Bellaire, Texas 77401, United States
  • Velocity Clin Res, Dallas
    Dallas, Texas 75230, United States
  • North Texas Endocrine Center
    Dallas, Texas 75231, United States
  • Synexus Clin Res Dallas
    Dallas, Texas 75234, United States
  • Cedar Health Research
    Dallas, Texas 75251, United States
  • PrimeCare Medical Group
    Houston, Texas 77024, United States
  • JCCT- Juno NW Houston
    Houston, Texas 77040, United States

Showing the first 100 of 197 sites across 8 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2024 to primary completion in Mar 2026, 25 months.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 25 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2024
First posted
Jan 24, 2024
StartActual
Jan 16, 2024
Primary completionActual
Mar 4, 2026
CompletionActual
Apr 6, 2026
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06221969
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jan 24, 2024
Start date
Jan 16, 2024
Primary completion
Mar 4, 2026
Completion
Apr 6, 2026
Last update
Oct 19, 2026

Study contacts

Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cagrilintide

Start the discussion